|
Title
|
Status
|
|
|
Recruiting
in 22 of 23 locations
|
|
To determine if Accelerated Partial Breast Irradiation, using 3D CRT, is as effective as
Whole Breast Irradiation following breast conserving surgery in women with an new
histological diagnosis of ductal carcinoma in situ only or invasive breast cancer without
evidence of metastatic disease. Effectiveness will be determined by the rate of ipsilateral
breast tumour recurrence.
General objective is to improve the convenience and quality of life of female patients who
receive breast irradiation.
|
|
|
Recruiting
in 3 of 4 locations
|
|
The objective of this study is to compare the long-term efficacy of pasireotide LAR vs. octreotide LAR in controlling diarrhea and flushing in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by the maximum approved doses of somatostatin analogues.
|
|
|
Recruiting
in 6 of 7 locations
|
|
The primary goal of this study is to determine the rate of confirmed best cumulative
complete molecular response within the first year of study therapy with imatinib or
nilotinib. The study will also explore the impact and significance of the achieved CMR on
patient outcomes (PFS, EFS and OS), characterize the kinetics of CMR achieved in both
treatment arms and after the cross-over.
|
|
|
Recruiting
in 3 of 3 locations
|
|
The purpose of this study is to determine if lenalidomide (Revlimid®) is safe and effective as a maintenance therapy at improving further the quality of the response you achieved with your last therapy and at prolonging the duration of your response. This study will compare the effects (good and bad) of lenalidomide with the dummy drug.
|
|
|
Recruiting
in 9 of 12 locations
|
|
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy, such as goserelin, leuprolide, or bicalutamide, may lessen the amount of androgens made by the body. Giving radiation therapy together with androgen deprivation therapy may kill more prostate cancer cells. PURPOSE: This randomized phase III trial is studying how well giving radiation therapy together with androgen deprivation therapy works in treating patients who have undergone surgery for prostate cancer.
|
|
|
Recruiting
in 5 of 5 locations
|
|
The hypothesis of the proposed study would be that, due to the six months of total androgen blockade, which would include neoadjuvant hormonal therapy for four months and concomitant hormonal therapy for two months with irradiation, the investigators could reduce local failure rates for these two dosage levels, namely 70 Gy and 76 Gy. Since increasing the dose to the prostate also seems to reduce local relapse rates, the results of the two hormonal therapy groups would be compared with the results of prostate irradiation at doses of 76 Gy. This study would verify the possibility of compensating a six Gy dosage increase of radiation therapy with six months of hormonal therapy between the 70 Gy and 76 Gy groups who received hormonal therapy, and also match these results with a dose escalation to the prostate of 76 Gy. In the future, this could result in more therapeutic choices, such as reducing the doses of radiation therapy and, consequently, its related complications, if hormonal therapy proves to be beneficial; or rather, to continue in the direction of dose escalation for this intermediate-risk patient group, everything being correlated to the side effects of hormonal therapy and irradiation.
|
|
|
Recruiting
in 11 of 11 locations
|
|
This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST).
|
|
|
Recruiting
in 2 of 2 locations
|
Amonafide is a DNA intercalating agent and inhibitor of topoisomerase II that has been extensively studied in patients with malignant solid tumours. Amonafide has also been studied in patients with AML. In three Phase I clinical trials, amonafide demonstrated anti-leukemic activity, both as monotherapy and in combination with cytarabine. In a recent single-arm Phase II study of amonafide together with standard infusion of cytarabine in patients with sAML, the overall CR rate was 43%, which compare favorably with CR rates of 24 and 26% following 7 & 3 treatment of secondary AML in the SWOG studies 9031 and 9333.
The purpose of this study is to assess the relative efficacy and safety of amonafide in combination with cytarabine compared to daunorubicin with cytarabine in subjects with documented secondary AML.
The duration of the study is approximately 42 months: enrollment approximately 18 months and subject duration up to 24 months.
|
|
|
Recruiting
in 3 of 4 locations
|
|
The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as measured by progression free survival (PFS) compared to standard chemotherapy (Paclitaxel or Doxorubicin) in women with advanced endometrial cancer that progressed after first line chemotherapy.
|
|
|
Recruiting
in 1 of 1 locations
|
Hypothesis: The reduction of total body iron by phlebotomy will be safe and feasible in the post-HSCT setting
Iron overload is common after hematopoietic stem cell transplantation. It is associated with chronic liver disease, with increased rates of infection and decreased survival.
Eligible, consenting patients will have once monthly phlebotomy procedures (500ml) for 12 months.
SAFETY: At each visit, patients will have a comprehensive assessment prior to starting and after completing the phlebotomy. This assessment will include determination of pain at phlebotomy site, local infection and an assessment of symptoms of anemia including presyncope, fatigue and dyspnea. The patient's pulse, blood pressure, respiratory rate and temperature will also be determined before and following the phlebotomy.
EFFICACY: Iron stores will be measured serially in each patient. Measurements will be performed prior to the start of phlebotomy, and at 6 months and 12 months following the start of the series of 12 phlebotomies. These evaluations will be undertaken regardless of the number of phlebotomies which the patient actually undergoes. Iron stores will be estimated by measuring serum ferritin and transferrin saturation levels. Total body iron will be estimated from hepatic and cardiac iron concentration as measured by magnetic resonance imaging (MRI). Gandon et al. (12) described a non-invasive technique using MRI to measure hepatic iron stores. Iron is a paramagnetic substance which causes local magnetic field inhomogeneities leading to dephasing and signal loss in MRI. Gradient echo sequences are most susceptible to their effects because they do not use a 180° refocusing pulse, unlike conventional spin-echo sequences. Gandon et al. used multiple gradient echo sequences, compared the signal in liver to adjacent muscle and used this ratio to correlate with hepatic iron levels measured on tissue biopsy samples using spectrophotometric analysis. Multiple sequences were used because the nomogram comparing the L/M signal ratio is linear over only a small concentration of tissue iron.
|
